RINVOQ Upadacitinib Application Scope

RINVOQ (Upadacitinib) is an oral selective JAK1 inhibitor used to treat moderate-to-severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and other autoimmune conditions.

RINVOQ Upadacitinib Characteristics

Ingredients: Upadacitinib (a Janus kinase [JAK] inhibitor)
Properties: Selective JAK1 inhibitor that modulates immune response by inhibiting the JAK-STAT signaling pathway, reducing inflammation associated with autoimmune diseases.
Packaging Specification: Extended-release tablets: 15 mg, 30 mg, 45 mg; Oral solution (RINVOQ LQ): 1 mg/mL
Storage: Store in the original blister or bottle with the lid tightly closed to protect from moisture. Does not require any special temperature storage conditions.
Expiry Date: As labeled on the container
Executive Standard: Meets FDA, EMA, and ICH Q6B standards for biologics
Approval Number: FDA Approval Number: 211675
Date of Revision: Refer to the latest FDA label for the most recent revision date
Manufacturer: AbbVie Inc.

Guidelines for the Use of RINVOQ Upadacitinib

Dosage and Administration:
- Recommended Dose: 15 mg orally once daily for most indications. Specific dosing may vary based on the condition being treated.
- Administration: Oral administration, either as extended-release tablets or oral solution.
- Missed Dose: If a dose is missed, take it as soon as possible unless it is close to the time for the next dose. Do not take two doses at the same time.
Adverse Reactions:
- Common Adverse Reactions: Upper respiratory tract infections, headache, nausea, and increased blood pressure.
- Serious Adverse Reactions: Serious infections, malignancies, thrombosis, and gastrointestinal perforations.
Contraindications: Hypersensitivity to upadacitinib or any component of the formulation.
Precautions:
- Infections: Monitor for signs of infection.
- Cancer: Evaluate for malignancies before starting treatment.
- Liver Function: Monitor liver enzymes during treatment.
- Blood Counts: Monitor complete blood counts regularly.

RINVOQ Upadacitinib Interactions

Drug Interactions: May interact with other immunosuppressive agents, live vaccines, and strong CYP3A4 inhibitors.
Alcohol: Limit alcohol consumption due to potential increased risk of side effects.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.